PESI 10-K & 10-Q changes, risk factors and insider trading
Perma Fix Environmental Services Inc. · Nasdaq · Hazardous Waste Management · CIK 891532 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
New heading “A lack of positive operating results could limit our borrowing capacity under our credit facility.”
Removed heading “Inability to maintain the required liquidity under our loan agreement with our lender could adversely affect our operations.”
Largest changes
Our credit facility with our bank contains financialsee in full comparisoncovenants.covenants,AincludingbreachrequirementsoftoanymaintainofminimumthesedailycovenantsLiquiditycould(definedresultunder ourinloanaagreementdefaultas borrowing availability under our revolving credit plus cash in our money market deposit account (“MMDA”)facilitymaintainedtriggeringwith our lender)to immediately require the repayment of all outstanding debt under our credit facility and terminate all commitments to extend further credit.amounts. Wewere not required to perform testing of our fixed charge coverage ratio (“FCCR”) in each of the quarters in 2024 but otherwisehave met all of ourotherfinancial covenantrequirements. In the past, we have failed to meet our minimum FCCR requirement in certain instances and in each case, our lender has either waived these instances of non-compliance or provided certain amendments to our FCCRrequirementswhichduringenabled us to meet our quarterly FCCR requirements. Also, our lender has in the past waived our FCCR testing requirement in certain quarters.2025. If we fail to meet any of our financial covenants goingforward, including the minimum quarterly FCCR requirement,forward and our lender does not waive the non-compliance or revise our covenant requirement so that we arearein compliance, our lender could accelerate the payment of our borrowings under our credit facility and terminate our credit facility. In such event, we may not have sufficient liquidity to repay our debt under our credit facility and other indebtedness and/or operate our business.
“We are required to maintain a certain level of Liquidity (defined as borrowing availability under the revolving credit plus cash in our money market deposit account (“MMDA”) maintained with our lender) under our credit facility. The maximum we can borrow under the revolving part of our credit facility is based on a percentage of the amount of our eligible receivables outstanding at any one time reduced by outstanding standby letters of credit and any borrowing reduction that our lender has or may impose from time to time. …”see in full comparison
“Inability to maintain the required liquidity under our loan agreement with our lender could adversely affect our operations.”see in full comparison
“In the period ended September 30, 2024, we identified a material weakness related to the precision level required to properly evaluate the need for a valuation allowance on our U.S. deferred tax assets. This material weakness resulted in an income tax valuation adjustment recorded during the quarter. The necessary level of precision was not applied when evaluating the need for a valuation allowance. The error was corrected by us in our condensed consolidated financial statements as of September 30, 2024, and for the three and nine months ended September 30, 2024. …”see in full comparison
“If we are unable to maintain adequate internal control over financial reporting or remediate any material weakness identified, there is a reasonable possibility that a misstatement of our annual or interim financial statements will not be prevented or detected in a timely manner. If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information, the market price of our Common Stock could decline significantly, and our business, financial condition, and reputation could be harmed.”see in full comparison
Maintaining effective internal control over financial reporting is necessary for us to produce reliable financial reports and is important in helpingsee in full comparisonhelpingto prevent financial fraud. If we are unable to maintain adequate internal controls, our business and operating results could be harmed. We are required to satisfy the requirements of Section 404 of Sarbanes Oxley and the related rules of the Commission, which require, among other things, management to assess annually the effectiveness of our internal control over financial reporting. If we are unable to maintain adequate internal control over financialreporting.reporting or remediate any material weakness identified, there is a reasonable possibility that a misstatement of our annual or interim financial statements will not be prevented or detected in a timely manner. If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information, the market price of our Common Stock could decline significantly, and our business, financial condition, and reputation could be harmed.
Full comparison: every changed paragraph (42)
Risks Relating to our Business and Operations:
On
an annual basis, Congress is required to approve appropriations bills that govern spending by each of the federal government agencies
and departments we support. When Congress is, or Congress and the Administration are, unable to agree on budget priorities or specifics,
and thus unable to pass annual appropriations bills on a timely basis, Congress typically enacts a continuing resolution (“CR”).
CRs generally allow federal government agencies and departments to operate at spending levels based on the previous fiscal year. When
agencies and departments operate on the basis of a CR, funding we expect to receive from clients for work we are already performing and
for new initiatives may be delayed or canceled. Congress and the Administration have from time to timetime, failed to agree on a CR, resulting
in temporary shutdowns of non-essential federal government functions and our work on such functions. Failures by Congress and the Administration
to enact appropriations bills in a timely manner can force federal government agencies and departments to shut down or to cancel, change,
or delay the implementation of existing or new initiatives. Such events may result in the loss of revenue and profit, or the deferral
of revenue and profit to later periods. There is also the possibility that Congress will fail to raise the U.S. debt ceiling when necessary
which, in addition to resulting in federal government shutdowns, could significantly impact the U.S. and global economy, affecting the
discretionary spending decisions of our non-governmental clients and affecting the capital markets and our access to sources of liquidity
on terms that are acceptable to us. The delayed funding or shutdown of many parts of the federal government, including agencies, departments,
programs, and projects we support, could have a substantial negative effect on our revenue, profit, and cash flows.
There is also the possibility that Congress will fail to raise the U.S. debt ceiling when necessary which, in addition to resulting in federal government shutdowns, could significantly impact the U.S. and global economy, affecting the discretionary spending decisions of our non-governmental clients and affecting the capital markets and our access to sources of liquidity on terms that are acceptable to us.
GovernmentChanges
in government regulation, policy and program decisions under the new Administrationprograms could impact our business, affecting our profitability and future
growth.
A
material amount of our revenuesrevenue is derived from various federal government contracts or subcontracts. Considerable uncertainties exist
regarding how future federal budget andContinuous program decisions under the new Administration will unfold. Program and policy decisionsdecision
changes that
havein beenthe implementedU.S. orfederal may be implementedgovernment could negatively impact our business. TheseRecent programsprogram and policiespolicy include,changes since the beginning of the
new Administration have included, among other things,
a scaled down government workforce. These programsworkforce and policiesfurther and the transition of employees from the government agencies with which
we do business could create delayschanges in wastepolicies receiptsrelated fromto federaltariffs.
Continued government clients, project, procurements, and contract awards. Additionally,
trade tensions orand restrictions on trade,trade including the tariffs that have been imposed, have resulted and could further result in retaliation
by imposing tariffs by other countries. The imposition of these tariffs bybetween the U.S. and other countries, including tariffs imposed by the U.S and other
countries could resultnegatively inaffect our business. These program and policy change effects may include disruption in
supply chains, increased
costs on products that we utilize in our business operations, reduce profitability on waste that we treat for
international clients and
increased cybersecurity threats, among other things. Shift in decreased priorities in government funding for
remediation projects
by the new administrationAdministration may also negatively impact our results of operations and financial conditions.
Demand
for our services has been, and we expect that demand will continue to be, subject to significant fluctuations due to a variety of factors
beyond our control, including, without limitation, economic conditions, reductions in the budget for spending to remediate federal sites
due to numerous reasons including, without limitation, the substantial deficits that the federal government has and is continuing to
incur, domestic political environment, and competing demands for federal funds that can pressure various areas. During economic downturns,
large budget deficits that the federal government and many states are experiencing, and other events beyond our control, including, but
not limited to the impact from public health events (such as COVID-19 or other unforeseen public health event),event, the ability of private
and government entities
to spend on waste services, including nuclear services, may decline significantly. Our operations depend, in
large part, upon governmental
funding (for example, the annual budget of the DOE) or specifically mandated levels for different programs
that are important to our
business could have a material adverse impact on our business, financial position, results of operations and
cash flow.
PublicNatural
health threats and outbreaks such as COVID-19 and natural disasters such as hurricanes and severe weather conditions and public health threats and outbreaks such as the COVID pandemic have previously
negatively impacted our results of operations. The direct impacts of these such events resulted in delayed waste shipments and temporary
shut-down of projects by certain of our customers, and delays in procurement, contract awards and planning on behalf of our government
clients which negatively impacted our revenue. Residual and lingering macroeconomic effects from these such events could again in the
future impact supply chain, workforce availability, and/or increased costs which could have a downward effect on our business, financial
condition and results of operations. Additionally, world conflicts occurring in various regions may lead to similar macroeconomic effects
which could have a downward effect on our business, financial conditions and results of operations. We may attempt to increase our sales
prices in order to maintain satisfactory margin; however, competitive pressures in our industry may have the effect of inhibiting our
ability to reflect these increased costs in the prices of our services that we provide to our customers and therefore reduce our profitability.
We
are engaged in highly competitive business in which most of our government contracts and some of our commercial contracts are awarded
through competitive bidding processes. We compete with national, regional firms and some international firms with nuclear and/or hazardous
waste services practices, as well as small or local contractors. Some of our competitors have greater financial and other resources than
we do, which can give them a competitive advantage. In addition, even if we are qualified to work on a new government contract, we might
not be awarded the contract because of existing government policies designed to protect certain types of businesses and under-represented
minority contractors. Although we believe we have the ability to certify and bid government contract as a small business, there are a
number of qualified small businesses in our market that will provide intense competition. For international business, which we continue
to focus on, there are additional competitors, many from within the country the work is to be performed, making winning work in foreign
countries more challenging. Competition places downward pressure on our contract prices and profit margins. From time to time, we have
not been awarded a contract due to one or more of the above competitive conditions. If we are unable to meet these competitive challenges,
resulting in our ability to be awarded contracts, we could lose market share and experience onan overall reduction in our profits.
Our
revenues may be earned under contracts that are fixed-price or maximum price in nature. A number of contracts in our Services Segment
are and have in past, been fixed-price or maximum price contracts. Fixed-price contracts expose us to a number of risks not inherent
in cost-reimbursable contracts. Under fixed price and guaranteed maximum-price contracts, contract prices are established in part on
cost and scheduling estimates which are based on a number of assumptions, including assumptions about future economic conditions, prices
and availability of labor, equipment and materials, and other exigencies. If these estimates prove inaccurate, or if circumstances change
such as unanticipated technical problems, difficulties in obtaining permits or approvals, changes in laws or labor conditions, supply
chain interruptions, weather delays, cost of raw materials, our suppliers’ or subcontractors’ inability to perform, and/or
other events beyond our control, such as the impact of public health events, cost overruns may occur and we could experience reduced
profits or, in some cases, a loss for that project. Errors or ambiguities as to contract specifications can also lead to cost-overruns.
If
we cannot maintain our governmental permits or cannot obtain required permits, we may not be able to continue or expand our operations.
We
are a nuclear services and waste management company. Our business is subject to extensive, evolving, and increasingly stringent federal,
state, and local environmental laws and regulations. Such federal, state, and local environmental laws and regulations govern our activities
regarding the treatment, storage, recycling, disposal, and transportation of hazardous and non-hazardous waste and low-level radioactive
waste. We must obtain and maintain permits or licenses to conduct these activities in compliance with such laws and regulations. Failure
to obtain and maintain the required permits or licenses would have a material adverse effect on our operations and financial condition.
If any of our facilities are unable to maintain currently-heldcurrently held permits or licenses or obtain any additional permits or licenses which
may be required to conduct its operations, we may not be able to continue those operations at these facilities, which could have a material
adverse effect on us.
Risks Related to Laws and Regulations:
Our
governmental contracts or subcontracts relating to DOE and DODDOW sites are a significant part of our business. Allowable costs under U.S.
government contracts are subject to audit by the U.S. government. Although we believe that we have complied with applicable environmental
regulations, if these audits result in determinations that costs claimed as reimbursable are not allowed costs or were not allocated
in accordance with applicable regulations, we could be required to reimburse the U.S. government for amounts previously received.
Our
operations are highly regulated and we are subject to numerous laws and regulations regarding procedures for waste treatment, storage,
recycling, transportation, and disposal activities, all of which may provide the basis for litigation against us. In recent years, the
waste treatment industry has experienced a significant increase in so-called “toxic-tort” litigation as those injured by
contamination seek to recover for personal injuries or property damage. We believe that, as our operations and activities expand, there
will be a similar increase in the potential for litigation alleging that we have violated environmental laws or regulations or are responsible
for contamination or pollution caused by our normal operations, negligence or other misconduct, or for accidents,accidents which occur in the course
course of our business activities. Such litigation, if significant and not adequately insured against, could adversely affect our financial
condition and our ability to fund our operations. Protracted litigation would likely cause us to spend significant amounts of our time,
effort, and money. This could prevent our management from focusing on our operations and expansion.
We
and our customers operate in a politically sensitive environment. Opposition by third parties to particular projects can limit the handling
and disposal of radioactive materials. Adverse public reaction to developments in the disposal of radioactive materials, including any
high-profile incident involving the discharge of radioactive materials, could directly affect our customers and indirectly affect our
business. Adverse public reaction also could lead to increased regulation or outright prohibition, limitations on the activities of our
customers, more onerous operating requirements or other conditions that could have a material adverse impact on our customers’
customers and our
business.
The
elimination or any modification of the Price-Anderson ActsAct’s indemnification authority could have adverse consequences for our business.
The
Atomic Energy Act of 1954, as amended, or the AEA, comprehensively regulates the manufacture, use, and storage of radioactive materials.
The Price-Anderson Act (“PAA”) supports the nuclear services industry by offering broad indemnification to DOE contractors
for liabilities arising out of nuclear incidents at DOE nuclear facilities. That indemnification protects DOE prime contractors, but
also similar companies that work under contract or subcontract for a DOE prime contract or transportingtransports radioactive material to or from
a site. TheCongress extended the indemnification authority under the PAA, including DOE’s ability to indemnify DOE contractors, to
December 31, 2065, as part of the DOEFurther underConsolidated theAppropriations PAAAct, was2024 extended(Public throughLaw 2025 by the Energy Policy Act of 2005.118-47).
Under
certain conditions, the PAA’s indemnification provisions may not apply to our processing of radioactive waste at governmental facilities
and may not apply to liabilities that we might incur while performing services as a contractor for the DOE and the nuclear energy industry.
If an incident or evacuation is not covered under PAA indemnification, we could be held liable for damages, regardless of fault, which
could have an adverse effect on our results of operations and financial condition. If such indemnification authority is not applicable
available in the future, our business could be adversely
affected if the owners and operators of new facilities fail to retain our services in
the absence of adequate commercial adequate insurance and
indemnification.
Risks Relating to our Financial Performance and Position and Need for Financing:
If
any of our permits, other intangible assets, and tangible assets becomesbecome impaired, we may be required to record significant charges to
earnings.
Our
credit facility with our bank contains financial covenants.covenants, Aincluding breachrequirements ofto anymaintain ofminimum thesedaily covenantsLiquidity could(defined resultunder
our inloan aagreement defaultas borrowing availability under our revolving credit plus cash in our money market deposit account (“MMDA”)
facilitymaintained triggeringwith our lender) to immediately require the repayment of all outstanding debt under our credit facility and terminate all
commitments to extend further credit.amounts. We were not required to perform testing of our fixed charge coverage ratio (“FCCR”)
in each of the quarters in 2024 but otherwisehave met all of our other financial covenant requirements. In the past, we have failed to meet
our minimum FCCR requirement in certain instances and in each case, our lender has either waived these instances of non-compliance or
provided certain amendments to our FCCR requirements whichduring enabled us to meet our quarterly FCCR requirements. Also, our lender has in
the past waived our FCCR testing requirement in certain quarters.2025. If we fail to meet any of our
financial covenants going forward, including
the minimum quarterly FCCR requirement,forward and our lender does not waive the non-compliance or revise our covenant requirement so that we are
are in compliance, our lender could accelerate the payment of our borrowings under our credit facility and terminate our credit facility.
In such event, we may not have sufficient liquidity to repay our debt under our credit facility and other indebtedness and/or operate
our business.
A lack of positive operating results could limit our borrowing capacity under our credit facility.
The maximum amount available for borrowing under the revolving portion of our credit facility is based on a percentage of our eligible accounts receivable outstanding at any given time, reduced by outstanding standby letters of credit and any discretionary borrowing base reductions imposed by our lender. As a result, our borrowing capacity fluctuates based on the level and quality of our receivables and the lender’s determinations. If we do not generate positive operating results, our accounts receivable and overall borrowing base could decline, which would reduce the amount available to us under the credit facility. A reduction in borrowing availability could limit our access to working capital and constrain our ability to fund operations, capital expenditures, and other business needs. Our ability to make scheduled principal and interest payments, refinance existing indebtedness, and borrow under our credit facility depends on our future operating performance and cash flows, which are subject to prevailing economic conditions and financial, competitive, business, and other factors, many of which are beyond our control. A limitation on our borrowing capacity could have a material adverse effect on our business, financial condition, and results of operations. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” for a discussion of management’s current liquidity expectations and assumptions.
Inability
to maintain the required liquidity under our loan agreement with our lender could adversely affect our operations.
We
are required to maintain a certain level of Liquidity (defined as borrowing availability under the revolving credit plus cash in our
money market deposit account (“MMDA”) maintained with our lender) under our credit facility. The maximum we can borrow under
the revolving part of our credit facility is based on a percentage of the amount of our eligible receivables outstanding at any one time
reduced by outstanding standby letters of credit and any borrowing reduction that our lender has or may impose from time to time. As
of December 31, 2024, we had no borrowing under the revolving part of our credit facility and our Liquidity, as defined under our credit
facility was approximately $33,905,000, which included approximately $28,898,000 cash in our MMDA account primarily from the sales of
our Common Stock completed in May 2024 and December 2024. These sales were consummated at a negotiated price. A lack of positive operating
results could have material adverse consequences on our ability to operate our business. Our ability to make principal and interest payments,
to refinance indebtedness, and borrow under our credit facility will depend on both our and our subsidiaries’ future operating
performance and cash flow. Prevailing economic conditions, interest rate levels, and financial, competitive, business, and other factors
affect us. Many of these factors are beyond our control.
In such an event, one or more of the following could occur:
We
could, among other things, be:
Any
of the foregoing could adversely impact our operating results, financial condition, and liquidity. Our ability to continue our operations
depends on our ability to generate profitable operations or complete equity or debt financings to increase our capital.capital, Seewhen above risk
factor for a discussion as to raising Liquidity in connection with our equity financing.needed.
WeThe
haveCompany approximatelyhas $33,470,000 and $81,775,000 inestimated net operating loss carryforwards (“NOLs”) for federalfederal, state and stateforeign income tax purposes,purposes. respectivelyAll of
our NOLs can be carried forward and expiresapplied against future taxable income, if any, and expire in various amounts starting in 20242026 ifwith
the notexception used against future federal and state income tax liabilities, respectively. All
of our federal netNOLs operating loss carryforwards were generated after December 31, 2017 and thuswhich do not expire. Our net loss carryforwards
are subject to various limitations. Our ability to
use the net loss carryforwards depends on whether we are able to generate sufficient
income in the future years. GivenDue to our financial
performances in recent financial performance,years, we fully reserved these loss carryforwards in 2024. Further, our
net loss carryforwards have not been audited
or approved by the Internal Revenue Service.
We
sustained substantial losses in each of the years 2025 and 2024 and our inability to become profitable on an annualizeannual basis in the foreseeable future
could have
a material adverse effect on our operations, credit facility, liquidity and potential growth.
The
Company sustained substantial losses in each of the years 2025 and 2024. We believe that our results of operations should substantially improve in 2025.2026. If, however,
we fail to become profitable on an annualized basis in the foreseeable future, this could have a material adverse effect on our operations,
credit facility, liquidity and potential growth. See “Management’s Discussion and Analysis of Financial Condition
and Results of Operations—Liquidity and Capital Resources” for a discussion of management’s current liquidity expectations
and assumptions.
Risks Relating to our Common Stock:
Any
sales of substantial amounts of our Common Stock in the public market could cause an adverse effect on the market price of our Common
Stock and could impair our ability to raise capital through the sale of additional equity securities. The issuance of our Common Stock
will result in the dilution in the percentage equity interest of our stockholders and the dilution
in ownership value. During 2024, we
raised capital through the sales of our Common Stock in May 2024 (2,051,282 shares) and December 2024 (2,530,000 shares). As of December
31, 2024, we had 18,377,237 shares of Common Stock outstanding. In addition, as of December 31, 2024, we had outstanding options to purchase
1,000,900 shares of our Common Stock at exercise prices ranging from $3.15 to $10.20 per share and warrants to purchase 188,038 shares
of our Common Stock at exercise prices of $11.50 and $12.19 per share. Future sales of the shares issuable could also depress the market
price of our Common Stock.
General Risk Factors:
We
may not be successful in winning new business mandates from our government, commercial or international customers.
We
must be successful in winning mandatesbusiness from our government, commercial and international customers
to replace revenues from projects
that we have completed or that are nearing completion and to increase our revenues. We bid on numerous projects, and a number of the
projects we bid on, weand are not always successful in obtaining.being selected as the winning bid. Our business and operating results can be adversely affected
by the size and
timing of a single material contract.
There
is also an increasing attention on the importance of cybersecurity relating to infrastructure. This creates the potential for future
developments in regulations relating to cybersecurity that may adversely impact us, our customers and how we offer our services to our
customers.
Maintaining
effective internal control over financial reporting is necessary for us to produce reliable financial reports and is important in
helping helping
to prevent financial fraud. If we are unable to maintain adequate internal controls, our business and operating results
could be harmed.
We are required to satisfy the requirements of Section 404 of Sarbanes Oxley and the related rules of the
Commission, which require,
among other things, management to assess annually the effectiveness of our internal control over
financial reporting. If we are unable to maintain adequate internal control over financial reporting.reporting or remediate any material weakness identified, there is a reasonable
possibility that a misstatement of our annual or interim financial statements will not be prevented or detected in a timely manner.
If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information, the market
price of our Common Stock could decline significantly, and our business, financial condition, and reputation could be
harmed.
In
the period ended September 30, 2024, we identified a material weakness related to the precision level required to properly evaluate the
need for a valuation allowance on our U.S. deferred tax assets. This material weakness resulted in an income tax valuation adjustment
recorded during the quarter. The necessary level of precision was not applied when evaluating the need for a valuation allowance. The
error was corrected by us in our condensed consolidated financial statements as of September 30, 2024, and for the three and nine months
ended September 30, 2024. The material weakness noted did not result in a material misstatement in our previously issued financial statements,
nor in the financial statements included in our Quarterly Report on Form 10-Q for the period ended September 30, 2024. We have remediated
this material weakness as of December 31, 2024 (see “Item 9A. – Controls and Procedures” for a discussion of the remediation
of this material weakness).
If
we are unable to maintain adequate internal control over financial reporting or remediate any material weakness identified, there is
a reasonable possibility that a misstatement of our annual or interim financial statements will not be prevented or detected in a timely
manner. If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information, the market
price of our Common Stock could decline significantly, and our business, financial condition, and reputation could be harmed.
We are a Delaware corporation governed by the Delaware General Corporation Law. In general, Section 203 prohibits a Delaware public corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. As a result of Section 203, potential acquirers may be discouraged from attempting to effect acquisition transactions with us, thereby possibly depriving our security holders of certain opportunities to sell, or otherwise dispose of, such securities at above-market prices pursuant to such transactions. Further, certain of our option plans provide for the immediate acceleration of, and removal of restrictions from, options and other awards under such plans upon a “change of control” (as defined in the respective plans). Such provisions may also have the result of discouraging acquisition of us. All of our authorized preferred stock are available for issuance. Future sales of authorized and unissued shares could be used by our management to make it more difficult for, and thereby discourage, an attempt to acquire control of us.
As
of December 31, 2024, out of 30,000,000 shares of our Common Stock authorized, we had 18,377,237 shares of Common Stock outstanding and
7,642 shares of treasury stock. In addition, as of December 31, 2024, we had outstanding options to purchase 1,000,900 shares of our
Common Stock at exercise prices ranging from $3.15 to $10.20 per share and warrants to purchase 188,038 shares of our Common Stock at
exercise prices of $11.50 and $12.19 per share. Assuming the issuance of the Common Stock underlying such options and warrant, as of
December 31, 2024, we had available for future issuance 10,426,183 shares of authorized and unissued Common Stock, and 2,000,000 shares
of our preferred stock. All of our authorized preferred stock ae available for issuance. Future sales of authorized and unissued shares
could be used by our management to make it more difficult for, and thereby discourage, an attempt to acquire control of us.
Management's Discussion & Analysis (MD&A)
Removed heading “Perma-Fix Canada Inc. (“PF Canada”)”
Removed heading “Sale of Common Stock (May 2024)”
Removed heading “Sale of Common Stock (December 2024)”
Largest changes
“Market Trends and Uncertainties. Macroeconomic conditions which include recent government and policy changes implemented in the United States, government budget issues, tariff actions and uncertainties related to trade wars, ambiguity around interest rates, softening labor markets and geopolitical instability, including ongoing conflicts and unrest in the Middle East, have created significant uncertainty in the global economy, volatility in the capital markets and recessionary pressures. …”see in full comparison
“Our financing activities for 2024 included monthly principal payments on a note that we entered into on July 24, 2024, to finance the balance of the purchase price of the property where our EWOC facility operates. Pursuant to a Purchase and Sales Agreement dated April 30, 2024, we acquired the property for a purchase price of $425,000, paying $63,750 in cash and financing the balance with a bank loan of $361,250 (the “Note”). …”see in full comparison
“Environmental Liabilities. We have three remediation projects in progress (all within discontinued operations). These remediation projects principally entail the removal/remediation of contaminated soil and, in most cases, the remediation of surrounding ground water. These remediation activities are closely reviewed and monitored by the applicable state regulators and often span multiple years. Remediation liabilities include costs for investigation, assessment, remediation, post-remediation monitoring, and related legal and consulting services. …”see in full comparison
“Our cash flow requirements during the twelve-months ended December 31, 2024, were primarily financed by our Liquidity (defined as borrowing availability under the revolving credit plus cash in our MMDA maintained with our lender). Our Liquidity included net proceeds received from the sales of an aggregate 4,581,282 shares of our Common Stock pursuant to certain Securities Purchase and Underwriting Agreements executed in May 2024 and December 2024 (see “Financing Activities” below for a discussion of these offerings, including the planned usage of the proceeds). …”see in full comparison
“Our cash flow requirements during the twelve months ended December 31, 2025, were financed by our Liquidity (defined under our Loan Agreement as borrowing availability under our Revolving Credit of our Credit Facility plus cash in our MMDA maintained with our lender). Our MMDA consists of cash received in connection with the sale of our Common Stock completed in 2024 as discussed below under “Financing Activities.””see in full comparison
“Although we are disappointed with our 2024 financial results, we believe our base business is positioned for improvement and that our results of operations should improve in 2025. We continue to advance a number of initiatives which are discussed within this report on Form 10-K. Some of these initiatives have been realized, with additional initiatives that are expected to be more fully realized in 2025. …”see in full comparison
Full comparison: every changed paragraph (89)
In 2025, we generated modest consolidated revenue growth year-over-year, while delivering improvements in gross profit and operating performance compared to the prior year, driven primarily by a rebound in the Treatment Segment. The Treatment Segment benefited from higher waste volumes and higher averaged price waste mix, which included higher revenue generated from international and commercial clients. In contrast, the Services Segment experienced lower revenue, due in part to delays in project mobilization and delays in procurements that resulted from changes to the current presidential administration that began in January 2025 (the “Administration”) and supporting policies that occurred in the first half of 2025. The partial government shutdown that occurred effective October 1, 2025, also negatively impacted our revenue as procurement timing cycles were impacted.
Overall revenue increased by $2,557,000 or 4.3% to $61,674,000 in 2025 as compared to $59,117,000 in 2024. The increase was entirely from our Treatment Segment where revenue increased by $10,144,000 or approximately 29.0% to $45,097,000 for the twelve months ended December 31, 2025, from $34,953,000 in the same period of 2024. Services Segment revenue decreased $7,587,000 or 31.4% to $16,577,000 for the twelve months ended December 31, 2025, from $24,164,000 for the same period of 2024. Gross profit increased by $5,971,000 or approximately 298,550% for the twelve months ended December 31, 2025, as compared to the corresponding period of 2024. Selling, General, and Administrative (“SG&A”) expenses increased by $1,925,000 or 13.3% for twelve months ended December 31, 2025, as compared to the corresponding period of 2024. In spite of the improvement in gross profit, we experienced a loss from continuing operations of approximately $10,665,000 in 2025. While the loss was disappointing, it reflected an improvement of approximately 45.5% from the 2024 loss from continuing operations of $19,569,000.
See “Results of Operations” below for discussions of certain financial metrics pertaining to our operations, which includes our two reportable segments.
We believe we are positioned for potential improvements in our financial results in 2026. These expectations are based on management’s current assumptions regarding the timing and execution of anticipated waste treatment volumes, including the commencement and ramp-up of activities associated with the Direct-Feed-Low-Activity Waste (“DFLAW”) program at Hanford, Washington, as well as our ability to convert existing Treatment Segment backlog into revenue. Treatment Segment backlog as of December 31, 2025, was approximately $11,861,000, representing an increase of approximately 50.9% from Treatment Segment backlog of $7,859,000 as of December 31, 2024. However, Treatment Segment backlog does not guarantee immediate revenue, as the timing of backlog processing may vary based on waste complexity, customer requirements, and operational considerations. As noted above, however, we believe that our Perma-Fix Northwest Richland, Inc. (“PFNWR”) treatment facility, immediately adjacent to the Hanford Nuclear Site, is positioned to support the U.S. Department of Energy’s (“DOE”) DFLAW program at Hanford, which began hot commissioning of the Low-Activity Waste Vitrification Facility in October 2025. The subsequent operational phase of the DFLAW program is anticipated to begin in 2026, which will include generation of several effluent waste streams expected to be treated by our PFNWR facility. However, the commencement, scope, and timing of DFLAW-related waste streams are controlled by the DOE and subject to appropriations, procurement processes, and operational considerations beyond our control. Delays in anticipated waste treatment volumes, including DFLAW-related waste streams, could impact our results of operations as we continue to incur fixed operating costs and capital expenditures in anticipation of waste treatment volumes and program activities.
We continue to focus on expansion into international markets which is reflected in revenue generated from foreign entities of approximately $6,440,000 in 2025, as compared to $2,452,000 in the corresponding period of 2024, an increase of $3,988,000 or 162.6%. Additionally, we continue our aggressive research and development (“R&D”), sales and marketing efforts and capital expenditures relating to our new patent-pending technology for the destruction of Per- and polyfluoroalkyl substances (“PFAS”), which activities adversely impacted our results of operations in 2025 (See “Known Trends and Uncertainties – New Processing Technology” for a discussion of our new PFAS-destruction technology).
We
were disappointed with our 2024 financial results, which were negatively impacted by a number of unexpected events and factors. These
events and factors included among other things,
As
a result of the aforementioned events and factors, overall revenue decreased by $30,618,000 or 34.1% to $59,117,000 for the twelve-months
ended December 31, 2024, from $89,735,000 for the corresponding period of 2023. Treatment Segment revenue decreased by $8,524,000 to
$34,953,000 or 19.6% from $43,477,000, and Services Segment revenue decreased by $22,094,000 or 47.8% to $24,164,000 from $46,258,000.
Total gross profit for the twelve-months ended December 31, 2024, decreased $16,367,000 or 100.0% due to decreased revenue generated
in both segments. Selling, general and administrative (“SG&A”) expenses decreased $484,000 or 3.2% for the twelve-months
ended December 31, 2024, as compared to the corresponding period of 2023.
During
2024, we provided a full valuation allowance against our deferred tax assets (see a discussion of this valuation allowance and the impact
to our financial statements in “Results of Operations – Income Taxes” below).
In
2024, we completed two public equity raises and sold an aggregate 4,581,282 shares of our Common Stock. See “Liquidity and Capital
Resources - Financing Activities” within this MD&A for discussions of these equity raises that occurred in May 2024 and December
2024.
Although
we are disappointed with our 2024 financial results, we believe our base business is positioned for improvement and that our results
of operations should improve in 2025. We continue to advance a number of initiatives which are discussed within this report on Form 10-K.
Some of these initiatives have been realized, with additional initiatives that are expected to be more fully realized in 2025. In December
2024, BWXT Technologies, Inc (“BWXT”) announced that the DOE had awarded BWXT and its team, which we are a member of, the
contract for the cleanup operations at the West Valley Development Project in West Valley, NY. As disclosed by BWXT, the contract has
a 10-year ordering period with a maximum value of up to $3 billion that can be performed for up to 15 years. The scope attributable to
us has not yet been defined and is subject to certain approvals. The West Valley Project is anticipated to begin transition in the first
quarter of 2025 and realize full operations in 120 days from initiation. As previously disclosed, in December 2023, we and our partner,
Campoverde Srl, each owning 50% of the partnership, were awarded a multi-year contract for the treatment of radioactive waste from the
Joint Research Center in Ispra, Italy. Revenue generated and to be generated by us from this contract has been and will be limited to
project management support through 2025. The scope of work in the initial phases of this contract is being performed predominantly by
our partner. We expect to generate an increase in revenue under this contract starting in 2026 when the waste treatment phases begin.
OurFinally,
our continuing initiatives include, among other things, positioning ourselves for further large and mid-size procurements within the DOE
and DODU.S. Department of War (“DOW”) and waste treatment in support of DOE’s
Hanford closure strategy, continuedcontinuing investments in our facilities and capabilities
to allow for broader waste treatment (including PFAS) (see “Known Trends
and Uncertainties - New Processing Technology” within
this MD&A for a discussion of our PFAS technology), and continuedcontinuing expansion of our waste treatment offerings within the international
and commercial markets (see “Part I, Item 1 – Business – Foreign Revenue and Initiatives” for a discussion of
our foreign revenue and initiatives).market.
We are continually monitoring our operating costs to ensure alignment with our revenue levels.
See
“Known Trends and Uncertainties – Federal Funding” within this MD&A for a discussion of factors that could impactsimpact
our results of operations in 2025.2026.
Our
Treatment and Services Segments’ business continuescontinue to be heavily dependent on services that we provide to federal governmental
clients, primarily as subcontractors for others who are contractors to government entities or directly as the prime contractor. We believe
demand for our services will continue to be subject to fluctuations due to a variety of factors beyond our control, including, without
limitation, current economic and political conditions, government reductions, passage of government budgets and continuing resolutions
(“CRs”), and the manner in which the applicable government authority will be required to spend
funding to remediate various sites and potential future federal budget issues.
sites. In addition, our governmental contracts and subcontracts
relating to activities at federal governmental sites in the United States are generally subject
to termination for convenience at any
time time, at the government’s option. Significant reductions in the level of governmental fundingfunding,
government shutdown or specifically mandated levels for
different programs that are important to our business could have a material adverse
impact on our business, financial position, results
of operations, liquidity and cash flows.
Consolidated
revenues decreasedincreased $30,618,000$2,557,000 for the year ended December 31, 2024,2025, compared to the year ended December 31, 2023,2024, as follows:
1)
Includes wasteswaste generated by government clients of $2,898,000$2,269,000 and $2,943,000$2,898,000 for the twelve months ended December 31, 2024,2025, and 2024,
2023, respectively.
Treatment
Segment revenue decreasedincreased by $8,524,000$10,144,000 or 19.6%29.0% for the twelve-months ended December 31, 2024,2025, over the same period in 2023.2024. The overall
decreaseincrease in revenue in the Treatment Segment revenue was primarily due to lowerhigher waste volume attributedand from the factors as discussed in the “Overview” section
above. Overall lowerhigher averaged price from waste mixmix. within the Our
Treatment Segment revenue was also contributedpositively impacted by our international initiatives, which generated an increase in revenue of approximately
$3,832,000 or 201.7%, to $5,732,000, as compared to $1,900,000, for the revenuesame decrease.period of last year. Services Segment
revenue decreased
by approximately $22,094,000$7,587,000 or 47.8%.31.4%. The decrease in revenue in the Services Segment was due to the reasons as discussed
in the “Overview” above.
section. Additionally, our Services Segment revenues are project based; as such, the scope, duration, and
completion of each project
vary.
Cost
of goods sold for the Treatment Segment decreasedincreased by approximately $538,000$4,240,000 or 1.5%.11.8%. Treatment Segment’s overall variable costs
increased decreased
by approximately $1,467,000$1,675,000 primarily due to the following: overall material and supplies, lab, transportation, and outside services costs were higher by approximately
$3,371,000; variable payroll costs (overtime) were higher by approximately $426,000 due to increased waste volume production; and disposal
costs were lower transportation,by disposal,approximately lab$2,122,000. andWithin bonus/incentiveour costs.Treatment Segment, variable cost categories can fluctuate
based on waste mix. Treatment Segment’s
overall fixed costs increasedwere higher by approximately $929,000$2,565,000 resulting from the following:
salaries and payroll related expenses were higher
by $1,717,000$2,130,000 due to higher headcount and cost-of-living adjustments (“COLA”)
effected during the third quarter of 2025; regulatorygeneral expenses were higher by $376,000, mostly due to higher utility costs; travel expenses
were higher by approximately $123,000; maintenance expenses were higher by approximately $101,000$59,000 from overall general maintenance of
equipment and updates to facility security; depreciation expenses were higher by $106,000 due to more finance leases and equipment purchases;
and regulatory expenses were lower by approximately
$626,000 due$229,000 tofrom fullyfewer depreciatedregulatory AROs that occurred in the third quarter of 2023 in connection with our EWOC facility; maintenance costs
were lower by approximately $123,000; general expenses were lower by $111,000 in various categories; and travel expenses were lower by
approximately $29,000.matters. Services Segment cost of goods sold decreased $13,713,000
$7,654,000 or 37.3%33.2% primarily due to lower revenue. The decrease
in cost of goods sold was primarily due to overall lower salaries/payroll
related, outside services, and travel costs totaling approximately
$13,565,000 $7,180,000; lower depreciation expenses oftotaling approximately $220,000$44,000
as certain equipment became fully depreciated in 2025; lower general expenses of $49,000approximately $265,000 in various categories; and higheroverall
lower disposal, material and supplies expensesand ofregulatory costs totaling approximately $121,000.$165,000. Included within cost of goods sold is depreciation
and amortization expense
of $1,637,000$1,700,000 and $2,484,000$1,637,000 for the twelve months ended December 31, 2024,2025, and 2023,2024, respectively.
Gross
profit for the year ended December 31, 2024,2025, was $16,367,000$5,971,000 lowerhigher than 20232024 as follows:
Treatment
Segment gross profit decreasedincreased by $7,986,000$5,904,000 or approximately 116.1%531.9% and gross margin decreasedincreased to 10.6% % from (3.2)% from 15.8% primarily due
to to
lowerhigher revenue from lowerhigher waste volume,volume overalland lowerhigher averaged price waste mix. The increase in fixed costs within the Treatment Segment partially offset these improvements, negatively impacting gross
profit and gross margin. Services Segment gross profit increased by $67,000 or approximately 6.0% and gross
margin improved to 7.1% from waste4.6%. mixThe increases were attributed primarily to overall improved margin on projects and lower fixed costs
which were offset by the impact of our fixed cost structure. Services
Segment gross profit decreased by $8,381,000 or 88.3% primarily due to decreased revenue as discussed in the “Overview” above.
The decrease in gross margin from 20.5% to 4.6% was attributed to overall lower margin projects as the two large projects completed in
late 2023 were higher margin projects.revenue. Our overall Services Segment gross margin is impacted by our current projects which are competitively
bid on and will thereforetherefore, have varying margin structures.
SG&A
expenses decreasedincreased $484,000$1,925,000 for the year ended December 31, 2024,2025, as compared to the corresponding period for 20232024 as follows:
Administrative SG&A expenses were higher primarily due to higher salaries, payroll related expenses and stock option compensation expenses totaling approximately $558,000. The hiring of the Company’s COO in January 2025 and COLA increases to payroll effected during the third quarter of 2025 contributed to this increase. The remaining higher expenses in Administrative SG&A were primarily due to higher outside services expenses of approximately $425,000 from more legal and business-related matters and higher travel expenses of approximately $53,000 due to more travel by senior management. Treatment Segment SG&A expenses were higher primarily due to the following: salaries and payroll related expenses were higher by approximately $713,000 as more employee hours were allocated to marketing initiatives of our new PFAS technology and overall business development; general expense were higher by approximately $244,000 in various categories (which include higher tradeshow expenses of approximately $157,000); travel expenses were higher by $35,000; and outside services expenses were lower by approximately $14,000 from fewer consulting matters. Services Segment SG&A expenses were lower primarily due to the following: salaries and payroll related expenses were lower by approximately $57,000 as fewer employee hours were allocated in supporting administrative/marketing functions due to lower revenue; general expenses were lower by approximately $62,000 in various categories; outside services expenses were higher by approximately $10,000 due to more consulting matters; and travel expense were higher by approximately $20,000. Included in SG&A expenses is depreciation and amortization expense of $59,000 and $126,000 for the twelve months ended December 31, 2025 and 2024, respectively.
Administrative
SG&A expenses were lower primarily due to lower incentive expenses of approximately $540,000, which was offset by overall higher
expenses of $206,000 in various categories. Administrative SG&A expenses in 2023 included incentives earned in connection with the
Company’s management incentive plans (“MIPs”) and other employees’ bonus plans. Such incentives were not earned
in 2024. Treatment Segment SG&A expenses were higher primarily due to higher salaries and payroll related expenses of approximately
$420,000 which were offset by overall lower travel, outside services and general expenses totaling approximately $379,000. The decrease
in Services Segment SG&A was primarily due to lower outside services expenses of approximately $102,000 from fewer consulting and
legal matters and lower salaries and payroll related expenses of approximately $249,000. The overall lower SG&A expenses were offset
by higher credit loss expenses of approximately $160,000 as a certain account receivable was determined to be uncertain as to collectability
as of December 31, 2024. Included in SG&A expenses is depreciation and amortization expense of $126,000 and $84,000 for the twelve
months ended December 31, 2024 and 2023, respectively.
R&D
expenses increased by $611,000$119,000 for the twelve-monthstwelve months ended December 31, 2024,2025, as compared to the corresponding period of 20232024, primarily
due to expenses incurred in connection with our new PFAS technology.
Interest income increased by approximately $202,000 for the twelve-months ended December 31, 2025, as compared to the corresponding period of 2024. The increase in interest income in 2025 as compared to 2024 was primarily due to higher interest income earned from funds deposited into our money market deposit account (“MMDA”) from the two equity raises that were completed in May 2024 and December 2024, offset by lower interest income earned from our finite risk sinking fund from lower interest rate.
Interest
income increased by approximately $315,000 for the twelve-months ended December 31, 2024, as compared to the corresponding period of
2023. The increase was primarily due to higher interest income earned from our finite risk sinking fund from higher interest rates that
took effect starting in March 2023. Additionally, the increase in interest income resulted from more funds that we maintained in our
money market deposit accounts from the two equity raises that were complete in May 2024 and December 2024. The overall increase in interest
income from the above was reduced by interest income received in March of 2023 of approximately $60,000 in connection with the Employee
Retention Credit refund that we received.
Interest
expense increaseddecreased by approximately $150,000$243,000 for the twelve-monthstwelve months ended December 31, 2024,2025, as compared to the corresponding period of
2023.2024. The increasedecrease was attributed primarily tothe result of capitalization of approximately $231,000 in interest costs incurred on thedebt $2,500,000on termconstruction
of loanprojects dated July 31, 2023, underfor our credituse, facility
and the promissory note that we entered into on July 24, 2024, for the purchase ofparticularly our EWOCPFAS facility. The higher interest expense was
also attributed to more finance leases.reactors.
We
record a valuation allowance against our net deferred tax asset to the extent we determine it is more likely than not that such asset
will not be realized in the future. We regularly evaluate the probability that our deferred tax assets will be realized and determines
whether valuation allowances or adjustments thereto are needed. This determination involves judgement and the use of estimates and assumptions,
including expectations of future taxable income and tax planning strategies. We apply judgment to consider the relative impact of negative
and positive evidence, and the weight given to negative and positive evidence is commensurate with the extent to which such evidence
can be objectively verified. Based on our evaluation of all available positive and negative evidence, and with greater weight placed
on the objectively verifiable evidence which primarily included our three-year cumulative losses, we determined that it was more likely
than not that our net U.S. deferred tax asset will not be realized. As a result, in 2024, we provided a full valuation allowance against
our U.S. federal and state deferred tax assets and recorded an income tax expense in the amount of approximately $8,194,000. We continue
to maintain a valuation allowance against foreign tax attributes that may not be realized.
We
had income tax expenses of $4,435,000$0 and $17,000$4,435,000 for continuing operations for the twelve-months ended December 31, 20242025 and 2023,2024, respectively.
Our effective tax rates were approximately 29.3%0% and 1.8%(29.3%) for the twelve-monthtwelve months ended December 31, 20242025 and 2023,2024, respectively. Our effective
tax rate for the twelve-monthseach endedof Decemberthe 31,periods 2024,above was impacted primarily by theour income tax expense recorded in the amountrecognition of approximately
$8,194,000 as we provided for a full valuation allowance against our U.S.U.S federal and
state deferred tax assets.assets Our effective tax rate
forin the twelve-monthsquarter ended DecemberSeptember 31,30, 2023, was impacted by non-deductible expenses and state taxes.2024.
Our
Treatment Segment maintains a backlog of stored waste, which represents waste that has not been processed. The backlog is principally
a result of the timing and complexity of the waste being brought into the facilities and the selling price per container. As of December
31, 2024,2025, our Treatment Segment had a backlog of approximately $7,859,000,$11,861,000, as compared to approximately $8,702,000$7,859,000 as of December 31,
2023.2024. Additionally, the time it takes to process waste from the time it arrives may increase due to the types and complexities of the
waste we are currently receiving. We typically processuse our best efforts to increase treatment of our waste backlog during periods
period of lowlower incoming waste receipts,receipts to optimize facility utilization, which historically has been
occurred in the first orand fourth quarters.
Discontinued
Operations and Environmental ContingenciesLiabilities
Our
discontinued operations consist of all our subsidiaries included in our former Industrial Segment which encompasses subsidiaries divested
in in
2011 and earlier, as well as three previously closed locations.
Our
discontinued operations had no revenue for the twelve-monthstwelve months ended December 31, 20242025 and 2023.2024. We incurred net losses of $410,000$3,119,000 (net
of tax benefitexpense of $149,000$0) and $433,000$410,000 (net of tax benefit of $117,000$149,000) for our discontinued operations for the twelve-monthstwelve months ended December
December31, 31,2025, and 2024, and 2023, respectively. NetOur lossesnet loss for both2025 yearsincluded an increase to the environmental remediation reserve of approximately
$2,721,000 for our Perma-Fix of South Geogia, Inc. (“PFSG”) subsidiary as discussed below. The remaining net loss for 2025
and net loss for 2024 were primarily due to costs incurred in connection with management
of administrative and regulatory matters related
to our remediation projects. We have three environmental remediation projects, all within
our discontinued operations, which principally entail the removal/remediation of contaminated soil, and, in most cases, the remediation
of surrounding ground water.
We have three remediation projects, which are currently in progress relating to our Perma-Fix of Dayton, Inc. (“PFD”), Perma-Fix of Memphis (“PFM”) and PFSG subsidiaries, all within our discontinued operations. We divested PFD in 2008; however, the environmental liability of PFD was retained by us upon the divestiture of PFD. These remediation projects principally entail the removal/remediation of contaminated soil and, in most cases, the remediation of surrounding ground water. The remediation activities are closely reviewed and monitored by the applicable state regulators.
As of December 31, 2025, we had total accrued environmental remediation liabilities of $3,485,000, an increase of $2,718,000 from the December 31, 2024, balance of $767,000. The net increase of approximately $2,718,000 reflects an increase of approximately $2,721,000 made to the reserve at our PFSG subsidiary following a reassessment of remediation cost estimates after clarification of the remediation plan from the state regulator, offset by payments of approximately $3,000 for our PFSG remediation project. As of December 31, 2025, approximately $76,000 of our total environmental remediation liabilities were recorded as current.
Based on current operating conditions and the timing of anticipated waste receipts and program activities, we currently expect to incur a loss from operations during the first quarter of 2026. This expectation also reflects the timing of backlog processing, continued operating fixed costs and capital expenditures incurred in anticipation of program activities, including ongoing investments in new technology initiatives and with respect to the DFLAW program.
Despite the anticipated near-term operating loss, we believe that our existing cash, cash equivalents, borrowing availability under our Revolving Credit (see “Financing Activities – Credit Facility” below for a discussion of our Revolving Credit) and expected cash flows from operations will be sufficient to fund our operations for at least the next twelve months, based on management’s current assumptions regarding the timing and execution of anticipated waste treatment volumes.
Our cash flow requirements during the twelve months ended December 31, 2025, were financed by our Liquidity (defined under our Loan Agreement as borrowing availability under our Revolving Credit of our Credit Facility plus cash in our MMDA maintained with our lender). Our MMDA consists of cash received in connection with the sale of our Common Stock completed in 2024 as discussed below under “Financing Activities.”
We believe our cash flow requirements for the next twelve months will consist primarily of general working capital needs, scheduled principal payments on our debt obligations, administration and monitoring of our discontinued operations, R&D related to our PFAS technology and capital expenditures, including expenditures related to our PFAS technology (see “Known Trends and Uncertainties – New Processing Technology” within this MD&A for a discussion of this technology). We plan to fund these requirements from our operations and our Liquidity.
We continually review operating costs and evaluate opportunities to reduce operating costs and non-essential expenditures in order to align spending levels with revenue levels. As of December 31, 2025, we had no outstanding borrowing under our Revolving Credit and our Liquidity was approximately $18,126,000, which included approximately $11,529,000 of cash held in our MMDA.
Our
cash flow requirements during the twelve-months ended December 31, 2024, were primarily financed by our Liquidity (defined as borrowing
availability under the revolving credit plus cash in our MMDA maintained with our lender). Our Liquidity included net proceeds received
from the sales of an aggregate 4,581,282 shares of our Common Stock pursuant to certain Securities Purchase and Underwriting Agreements
executed in May 2024 and December 2024 (see “Financing Activities” below for a discussion of these offerings, including the
planned usage of the proceeds). We believe our cash flow requirements for the next twelve months will consist primarily of general working
capital needs, scheduled principal payments on our debt obligations, remediation projects, R&D on our PFAS technology and capital
expenditures (which include our PFAS technology) (see “Known Trends and Uncertainties – New Processing Technology”
within this MD&A for a discussion of this technology). We plan to fund these requirements from our operations and Liquidity under
our Credit Facility. We are continually reviewing operating costs and reviewing the possibility of further reducing operating costs and
non-essential expenditures to bring them in line with revenue levels. As of December 31, 2024, we had no outstanding borrowing under
our revolving credit and our Liquidity under our Credit Facility was approximately $33,905,000. We believe that our cash flows from operations
and our Liquidity should be sufficient to fund our operations for the next twelve months. Although we believe our operations should improve
in 2025, if we continue to incur losses such as in 2024, this could cause a reduction in our Liquidity.
As
of December 31, 2024,2025, we were in a positive cash position with no revolvingRevolving creditCredit balance. As of December 31, 2024,2025, we had cash on hand
of approximately $28,975,000.$11,768,000, which included cash from our foreign subsidiaries of approximately $153,000. The decline in our cash from
2024 to 2025 of approximately $17,207,000 was primarily due to funding of our operating losses and capital investment.
Cash used in operating activities of our continuing operations during 2025 consisted mostly of the net loss that we incurred of approximately $10,665,000, adjusted for certain non-cash items, such as $818,000 of stock-based compensation expenses and $1,759,000 of depreciation and amortization expenses. Cash flow decrease of approximately $2,921,000 resulting from net change in assets and liabilities reflects an increase in unbilled receivables of approximately $3,791,000, a net decrease in accounts payables, accrued expenses, deferred revenue and other accruals totaling approximately $1,660,000, offset by a decreased in accounts receivable (net of provision for credit losses) of approximately $216,000 and a net decrease in inventories, prepaids and other assets totaling approximately of $2,314,000. Our accounts receivables are impacted by timing of invoicing and collections. Our contracts with our customers are subject to various payment terms and conditions. Our unbilled receivables are impacted by differences between invoicing timing and our revenue recognition methodology.
Cash
used in operating activities of our continuing operations during 2024 consisted mostly of the significant net loss that we incurred of
approximately $19,569,000, adjusted for certain non-cash items, such as $656,000 of stock-based compensation expense, $1,763,000 of depreciation
and amortization expense and the deferred income tax expense of $4,448,000. TheCash flow decrease of approximately $2,229,000 resulting
from net change in assets and liabilities reflects an increase in accounts receivable of approximately $2,076,000 (net of provision for
credit losses), a net decrease in cashaccounts usedpayables, accrued expenses, deferred revenue and other accruals totaling approximately $6,667,000,
offset by a decreased in operatingunbilled activitiesreceivables of our
continuingapproximately operations$3,442,000 fromand 2023 to 2024 was driven primarily from the significanta net loss that we incurred. Our cash useddecrease in operatinginventories, prepaids and other assets
activitiestotaling approximately of our discontinued operations consisted primarily of expenses incurred in connection with management and administration of
regulatory matters for the Company’s remediation projects.$3,072,000.
Cash used in operating activities of our discontinued operations during 2025 and 2024 consisted primarily of expenses incurred in connection with management of administrative and regulatory matters related to our remediation projects.
We
had working capital of $28,283,000$13,803,000 (which included working capital of our discontinued operations) as of December 31, 2024,2025, as compared
to working capital of $4,613,000$28,283,000 as of December 31, 2023.2024. The improvement in ourdecrease in our working capital was primarily due to the increase
in our cash from the sales of our Common Stock in May 2024 and December 2024, which was offsetdriven by the significant losses incurred
from from
our results of operations attributedduring to the various factors2025 as previously discussed.discussed and increase in capital expenditures as discussed below.
Perma-Fix
Canada Inc. (“PF Canada”)
Our
cash used in operating activities in 2024 included receipt of certain outstanding receivables from Canadian Nuclear Laboratories, LTD
(“CNL”) as follows: During the fourth quarter of 2021, PF Canada received a Notice of Termination (“NOT”) from
CNL on a Task Order Agreement (“TOA”) that PF Canada entered into with CNL in May 2019 for remediation work within Ontario,
Canada (“Agreement”). The NOT was received after work under the TOA was substantially completed and work under the TOA has
since been completed. CNL may terminate the TOA at any time for convenience. At year-end 2023, PF Canada had approximately $2,389,000
in outstanding receivables due from CNL as a result of work performed under the TOA. A settlement agreement was reached between PF Canada
and CNL on the payment of the aforementioned amount by CNL, subject to certain conditions/terms precedents being met. PF Canada received
a partial payment from CNL of the outstanding receivables during the first quarter of 2024. In May 2024, PF Canada received the remaining
approximately $1,612,000 in outstanding receivables from CNL. As a result of the aforementioned payments received from CNL, no outstanding
receivables remain under the TOA from CNL.
Cash
used in investing activities of our continuing operations during 20242025 consisted mostly of our purchases of property and equipment totaling
approximately $3,811,000,$5,172,000, of which $406,000$464,000 was financed. Our capital expenditures for 2025 included expenditures made for our PFAS treatment
systems, which include our second-generation unit. The remaining cash used in investing activities consisted of cash outlays of approximately
$217,000 made
in connection with our operating permits and certain intangible assets. The increase inTotal cash used in investing activities of our
continuing
operations in 2024 as compared to 2023 was primarily due to capital expenditures made in connection with our PFAS technology which included
the installation of our first unit in treating PFAS. Cash used in investing activities of our discontinued operations was primarilypartially for
roofoffset replacementby atapproximately $28,000 from our PFSGsale location.of idle equipment.
Cash used in investing activities of our continuing operations during 2024 consisted mostly of our purchases of property and equipment totaling approximately $3,811,000, of which $406,000 was financed. Our capital expenditures for 2024 included expenditures made for our prototype PFAS treatment unit. The remaining cash used in investing activities consisted of cash outlays made in connection with our operating permits and certain intangible assets.
Cash used in investing activities of our discontinued operations during 2025 consisted of payments made in connection with a certain regulatory permit at our Perma-Fix South Georgia, Inc. (“PFSG”) subsidiary and improvements made to the existing building. Cash used in investing activities of our discontinued operations in 2024 was primarily for roof replacement at our PFSG location.
We
anticipate making capital expenditures of approximately $2,000,000$3,000,000 to $5,500,000$5,000,000 in 20252026 to maintain operations and regulatory compliance
requirements and support revenue growth.growth, We expect our capital expenditures to be higher in 2025 based on certain strategic project initiatives
which includeincluding the installationcompletion of our second generationsecond-generation unit for our PFAS technology. We plan to fund
our capital expenditures for 2025
2026 from cash from operations, Liquidity under our Credit Facility and/or financing. The initiation and
timing of our capital expenditures
are subject to a number of factors which include, among other things, cost/benefit analysis, the pace
of our strategic project initiatives
and improvement in our operations.
Our cash used in financing during 2025 consisted mostly of principal payments of approximately $631,000 primarily for our Term and Capital Loans under our Credit Facility, principal payments of $308,000 for our finance leases and payments of $195,000 of offering costs from the equity raise that we completed in December 2024, partially offset by proceeds received from option exercises of approximately $172,000.
Our
cash provided by financing during 2024 consisted mostly of net proceeds of $41,859,000 received from the sales of our Common Stock in
May 2024 and December 2024 as discussed below and proceeds received from option and a warrant exercises totaling approximately $292,000,
partially offset
by principal payments of approximately $832,000 primarily for our TermsTerm Loans and Capital Loan under our Credit Facility
(see below for a discussion of our Credit Facility) and $291,000
for our finance leases.
We
entered into a Second Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated May 8, 2020, which has since been
amended from time to time,amended, with PNC National Association (“PNC” and “lender”), acting as agent and lender (the
“Loan Agreement”).
The Loan Agreement provides us with the followinga credit facility with a maturity date of May 15, 2027
(the “Credit Facility”) which
consists of the following as of December 31, 2025: (a) up to $12,500,000 revolving credit (“revolvingRevolving creditCredit”), which borrowing
capacity is subject
to eligible receivables (as defined) and reduced by outstanding standby letters of credit ($3,200,000$3,350,000 as of December
31, 20242025) and borrowing
reductions that our lender may impose from time to time ($750,000 as of December 31, 20242025); (b) a term loan (“Term
Loan 1”)
of approximately $1,742,000, requiring monthly installments of $35,547 (Term Loan 1 was paid off by us in June 2024); (c) a term loan
(“Term Loan 2”) of $2,500,000, requiring monthly installments of $41,667$41,667, with a balance due under the Term Loan of approximately $1,333,000
as of December 31, 2025; and (dc) a capital expenditure loan (“Capital
Loan”) of approximately $524,000, requiring monthly
installments of principal of approximately $8,700 plus interest, thatwith commenceda balance due under the Capital Loan of approximately $149,000
onas Juneof 1,December 2022.31, 2025.
On
May 8, 2024 and November 12, 2024, we entered into amendments to our Loan Agreement with our lender which provided the following, among
other things:
In
connection with the amendments, we paid our lender fees totaling $37,500 which is being amortized over the remaining term of the Loan
Agreement as interest expense-financing fees.
In
connection with the amendment, the Company paid its lender a fee of $12,500.
Our
CreditAs Facility underamended, our Loan Agreement with PNC contains certain financial covenants,covenant requirements, along with customary representations and warranties.
A breach of any of these financial covenants,covenant requirements, unless waived by PNC, could result in a default under our CreditLoan FacilityAgreement allowing
our our
lender to immediately require the repayment of all outstanding debt under our CreditLoan FacilityAgreement and terminate all commitments to extend
further credit. We were not required to perform testing of our FCCR requirement for the first, second and third quarters of 2024 pursuant
to the amendments dated May 8, 2024, and November 12, 2024, to our Loan Agreement as discussed above. We were also not required to perform
testing of our FCCR requirement for the fourth quarter of 2024 pursuant to the amendment dated March 11, 2025, to our Loan Agreement,
as amended, as discussed above. Otherwise, we met all of our other financial covenant requirements in each of the quarters in 2024.2025. We
expect to meet our quarterly financial covenant requirements under our Loan
Agreement for the next twelve months.
EWOC
Note
What changed in the latest 10-Q
Risk Factors
New heading “We have sustained losses during 2024, 2025, and the first six months of 2026.”
Largest changes
“Our Liquidity (defined under our PNC Loan Agreement as borrowing availability under the Revolving Credit facility plus cash in our MMDA maintained with our lender) declined from $18,126,000 at December 31, 2025 to $10,720,000 at March 31, 2026, driven by ongoing operating losses, investments in PFAS technology, and infrastructure expansion, among other things. …”see in full comparison
“As described in Note 1 to our unaudited condensed consolidated financial statements, our recurring operating losses and negative cash flows from continuing operations have raised substantial doubt about our ability to continue as a going concern within one year after the date those financial statements are issued. …”see in full comparison
see in full comparisonWe have incurredOur recurring losses and negative operating cashflows, whichflows havereduced our liquidity and raiseraised substantial doubt about our ability to continue as a goingconcern.concern, and our expected improvement depends substantially on government-directed waste shipments and project activity that are outside our control.
“We have sustained losses during 2024, 2025, and the first six months of 2026.”see in full comparison
“The Company sustained significant losses during 2024, 2025, and the first six months of 2026. We believe that our results of operations should improve starting in the second half of 2026. If, however, we fail to become profitable on an annualized basis in the foreseeable future, this could have a material adverse effect on our operations, credit facility, liquidity and potential growth. Continuing losses may require us to seek additional liquidity through equity or other financing arrangements, potential asset dispositions, or other strategic alternatives. …”see in full comparison
There has been no other material change from the risk factors previously disclosed in our Form 10-K for the year ended December 31,see in full comparison2025,2025otherand Formthan10-Q for thebelow.quarter ended March 31, 2026, except as follows:
Full comparison: every changed paragraph (6)
There
has been no other material change from the risk factors previously disclosed in our Form 10-K for the year ended December 31, 2025,2025 otherand
Form than10-Q for the below.quarter ended March 31, 2026, except as follows:
We have sustained losses during 2024, 2025, and the first six months of 2026.
The Company sustained significant losses during 2024, 2025, and the first six months of 2026. We believe that our results of operations should improve starting in the second half of 2026. If, however, we fail to become profitable on an annualized basis in the foreseeable future, this could have a material adverse effect on our operations, credit facility, liquidity and potential growth. Continuing losses may require us to seek additional liquidity through equity or other financing arrangements, potential asset dispositions, or other strategic alternatives. We may also be required to reduce certain operating expenditures, including, but not limited to, reduction in R&D activities.
We have incurred Our
recurring losses and negative
operating cash flows, whichflows have reduced our liquidity and raiseraised substantial doubt about our ability to continue as a going concern.concern, and
our expected improvement depends substantially on government-directed waste shipments and project activity that are outside our control.
As described in Note 1 to our unaudited condensed consolidated financial statements, our recurring operating losses and negative cash flows from continuing operations have raised substantial doubt about our ability to continue as a going concern within one year after the date those financial statements are issued. Although the May 2026 equity offering significantly increased our liquidity, management concluded that the substantial doubt was not alleviated because a significant portion of the revenues and cash flows underlying our forecast depends on the timing and volume of waste shipments and project activity directed by U.S. government customers. Those customers do not provide binding assurances regarding the timing or volume of future work, and such activity is subject to appropriations, procurement processes, operational considerations and other factors outside our control. We expect that the operational developments and backlog discussed in this report may result in improved operating results during the second half of 2026; however, the timing and amount of any improvement remain subject to significant uncertainty.
Our Liquidity (defined under our PNC Loan Agreement
as borrowing availability under the Revolving Credit facility plus cash in our MMDA maintained with our lender) declined from
$18,126,000 at December 31, 2025 to $10,720,000 at March 31, 2026, driven by ongoing operating losses, investments in PFAS technology,
and infrastructure expansion, among other things. While we expect to fund operations through cash on hand, anticipated operating cash
flows, and availability under our Revolving Credit facility, these sources are subject to uncertainty, including federal budget constraints
and compliance with financial covenants. If these sources are insufficient, we may need to obtain additional financing or reduce expenditures,
including R&D, which could materially adversely affect our business.
Management's Discussion & Analysis (MD&A)
New heading “Financial Results Overview”
Removed heading “Capital Expenditures”
Largest changes
“These conditions and events, when considered in the aggregate, raise substantial doubt about our ability to continue as a going concern within one year after the date our condensed consolidated financial statements contained within this Form 10-Q are issued. We expect to fund our anticipated cash requirements from cash on hand, expected cash flows from operations, and borrowing availability under our Revolving Credit facility. …”see in full comparison
“Despite the positive developments discussed above, management concluded that substantial doubt continues to exist about our ability to continue as a going concern within one year after the date the accompanying Condensed Consolidated Financial Statements are issued (see “Liquidity and Capital Resources” within this MD&A for a discussion of the factors and conditions underlying this conclusion).”see in full comparison
“As a result of our recurring losses and negative operating cash flows, our liquidity has declined, which raises substantial doubt about our ability to continue as a going concern (See “Liquidity and Capital Resources” within this MD&A for a discussion of factors and conditions that raises substantial doubt about our ability to continue as a going concern).”see in full comparison
“Although the May 2026 equity offering discussed elsewhere in this Report strengthened our liquidity, we concluded that the substantial doubt was not alleviated. We expect our existing liquidity, anticipated operating cash flows and borrowing availability to be sufficient to fund our operations during the assessment period. However, the ability of our plans to mitigate the conditions giving rise to substantial doubt depends in part on the timing and volume of government-directed waste shipments and project activity, as well as other matters outside our control. …”see in full comparison
“Our cash flow requirements during the three months ended March 31, 2026, were primarily financed by our Liquidity, defined under our PNC Loan Agreement as borrowing availability under the Revolving Credit portion of our Credit Facility plus cash in our MMDA maintained with our lender.”see in full comparison
“A significant portion of our projected revenues and cash flows underlying our forecast depends on the timing and volume of waste shipments and project activity directed by U.S. government customers. Because these customers do not provide binding assurances regarding the timing or volume of future work, and such activity is subject to appropriations, procurement processes, operational considerations and other factors outside our control, we could not conclude that our plans are probable of effectively mitigating the conditions giving rise to substantial doubt. …”see in full comparison
Full comparison: every changed paragraph (103)
Our
forward-looking statements are based on the beliefs and assumptions of our management and the information available to our management
at the time these statements were prepared. Although we believe the expectations reflected in these statements are reasonable, we cannot
guarantee future results, levels of activity, performance, or achievements. You should not place undue reliance on thesethe forward-looking
statements,statements as noted above, which apply only to as of the date of this Annual Report on Form 10-K.10-Q. We undertake no obligation to update these forward-looking
statements, even if our situation changes in the future.
Our operating results for the second quarter of 2026 were below management’s expectations, primarily due to the timing of anticipated waste receipts, processing delays due to customer-directed changes in treatment protocols and continued strategic investments in support of future growth initiatives within our Treatment Segment. In addition, delays in the commencement of several new projects within our Services Segment and the continued processing of previously stored waste inventories to prepare for anticipated increases in certain Hanford-related waste volumes negatively impacted our revenues during the quarter, as described below. Despite these near-term impacts, the quarter marked an important operational milestone as our PFNW facility received certain Hanford-related waste streams as anticipated. These receipts contributed to an increase in our Treatment Segment backlog to approximately $15,733,000 at June 30, 2026, up approximately 28.5% from $12,248,000 at March 31, 2026. Subsequent to quarter-end, in early July, PFNW also began receiving liquid effluent wastes from the DFLAW facility, representing another significant operational milestone for the Company.
Although these operational milestones were achieved, our second quarter financial results did not reflect the benefit of the waste receipts discussed above. Customer-directed changes in treatment protocols delayed the processing of certain Hanford-related waste streams received during the second quarter into the third quarter. We expect to commence treatment of these wastes during the third quarter of 2026. At the same time, we incurred increased personnel and other operating expenses in anticipation of increases of these waste receipts; thus, while the revenue shifted to the second half, associated costs were incurred in the second quarter, which contributed to our losses for the period. In addition, as noted above, delays in the commencement of several new projects within our Services Segment and the continued processing of previously stored waste inventories to prepare for anticipated increases in certain Hanford-related waste volumes negatively impacted our revenues during the quarter. Certain of these previously stored waste inventories carried lower margins, which adversely affected our results of operations. These lower-margin previously stored waste inventories have now been substantially processed and are not expected to have a material effect on operating results during the next twelve months.
We believe the investments we have made in personnel, operational readiness, facility upgrades, capacity enhancements, as well as the acquisition of the rail-line land parcel that connects the PFNW property to the Port of Benton short-line railroad (see “Note 8 – Long-Term Debt – Promissory Note” to the accompanying Condensed Consolidated Financial Statements for further discussion of rail-line land parcel) have positioned us to support increasing Hanford-related activity. The commencement of Hanford-related waste receipts during the second quarter, the start of DFLAW liquid effluent waste receipts subsequent to quarter-end, the H2C contract award in August 2026 discussed below, and the growth in our Treatment Segment backlog indicate that these investments are beginning to translate into increased operating activity.
On August 10 2026, we were awarded a Master IDIQ Subcontract by Hanford Tank Waste Operations & Closure, LLC (“H2C”) for the treatment and disposal of pretreated liquid mixed low-level waste from DOE’s Hanford Site (the “Company’s Master Subcontract”). H2C also awarded Master IDIQ Subcontracts to two other companies. H2C is the prime contractor to DOE’s Office of Environmental Management for tank waste operations and closure at the Hanford Site in southeastern Washington State. Work awarded to us under future task orders, if any, under the Company’s Master Subcontract, would be performed at our PFNW facility in Richland, Washington and would include the receipt and treatment of pretreated mixed low-level waste, with treated waste transported by rail for final disposal at a licensed commercial mixed low-level waste disposal facility outside the State of Washington. Task orders may be issued from January 1, 2027 through December 31, 2041, with performance of task orders issued before the end of the ordering period permitted for up to five years beyond the end of the ordering period. The multiple-award IDIQ procurement provides for a maximum cumulative quantity of 50 million gallons, with a maximum cumulative value of approximately $4.4 billion. These amounts represent procurement ceilings shared among all Master IDIQ Subcontract holders and do not represent amounts awarded or committed to us. The number, size and timing of task orders to be issued to us, if any, cannot be assured. Under our Performance Work Statement, we are required to maintain the capability to treat and dispose of pretreated tank waste at a rate of 100,800 gallons per week in accordance with facility license and permit conditions.
Our PFNW facility is working with Washington State regulators regarding an expansion of its existing grouting permits and is advancing the design and procurement of facility upgrades intended to support the proposed expanded capacity.
Activity in our Services Segment is also increasing. During the first quarter of 2026, the segment was awarded a two-year master task agreement with an estimated value of approximately $24 million for demolition and disposal services at Lawrence Livermore National Laboratory (“LLNL”). In addition, during the second quarter we were awarded nearly $15 million of additional contracts supporting multiple DOE and commercial sites.
In May 2026, we completed a public equity raise and issued and sold an aggregate 2,628,571 shares of our Common Stock to fund capital investments and general working capital needs, including investments at our PFNW facility to support the Hanford waste program (see “Liquidity and Capital Resources – Financing Activities” within this MD&A and “Note 13 – Sale of Common Stock” to the accompanying Condensed Consolidated Financial Statements for further discussion of this equity raise).
Our
results from operations for the first quarter of 2026 were significantly impacted by lower revenues than anticipated due to reduced receipts
in conjunction with planned efforts to reduce waste inventories in support of second quarter anticipated receipts and program starts.
Our prioritization of processing existing waste inventories, particularly at the PFNWR facility,
and the associated timing of these activities deferred revenue recognition into the second quarter.
The
decrease in activity in the first quarter of 2026 was driven in part by deferred receipts now expected in the second quarter associated
with the commencement and ramp-up of the operational phase of DOE’s DFLAW program at Hanford Washington. The commencement, scope,
and timing of DFLAW-related waste streams are controlled by the DOE and subject to appropriations, procurement processes, and operational
considerations beyond our control.
Additionally,
seasonal factors, including winter weather and typical post-holiday slowdowns, reduced field activity and delayed waste shipments at
each of our plants.
In
anticipation of increased waste treatment volumes, including those under the DFLAW program, we have made investments to expand treatment
capacity, increase our trained workforce, and upgrade infrastructure. As previously disclosed, in December 2025, our PFNWR facility received
its long-awaited permit renewal from state regulators. Among other enhancements, this renewal approximately triples the facility’s
permitted liquid mixed waste processing capacity to approximately 1,200,000 gallons per year and authorizes the processing of up to 175,000
tons of waste annually through macroencapsulation. This expanded permit provides additional capacity and operational flexibility, enhancing
our ability to manage a broader range of complex waste treatment requirements. As waste volumes increase, we expect improved absorption
of our fixed operating costs, which we believe should positively impact operating margins.
As
a result of the combined foregoing factors, revenue for the first quarter of 2026 decreased by approximately $2,793,000, or 20.1%, to
$11,126,000, compared to $13,919,000, for the first quarter of 2025, reflecting lower revenue in both the Treatment and Services segments.
Overall cost of goods sold increased by $745,000 or approximately 5.6% for the first quarter of 2026, compared to the corresponding period
of 2025. Overall gross profit decreased by approximately $3,538,000 or 538.5% for the first quarter of 2026, compared to the corresponding
period of 2025, due to lower revenue, changes in waste and project mix across our segments and overall higher fixed costs.
Our
overall SG&A increased by $284,000 or 7.1% for the three months ended March 31, 2026, compared to the corresponding period of 2025.
See
below “Results of Operations” for further discussions of our financial results for our two segments.
As a result of our recurring losses and negative operating
cash flows, our liquidity has declined, which raises substantial doubt about our ability to continue as a going concern (See “Liquidity
and Capital Resources” within this MD&A for a discussion of factors and conditions that raises substantial doubt about our ability
to continue as a going concern).
WeLooking
believeahead, we arebelieve positionedour current initiatives position us for potential improvementsimprovement in our financial results forduring the remainder of 2026.
These We anticipate that our continuing
initiatives include positioningpursuing ourselves for furtheradditional large and mid-size procurementsprocurement opportunities within the DOE and DOWDOW, including opportunities
under the Hanford waste program, as well as expanding our presence in commercial and wasteinternational treatment in support
of DOE’s Hanford closure strategy. During the first quarter of 2026, our Services Segment was awarded a two-year master task agreement
which we believe to be valued at approximately $24 million for demolition and disposal at Lawrence Livermore National Laboratory.markets.
Additionally,
we continue to focus on expansion into commercial and international markets. Furthermore, we are continuing our aggressive R&D, sales
and marketing efforts and capital expenditures related to our new patent-pending technology for the destruction of PFAS. These activities
adversely impacted our results of operations for the first quarter of 2026 but are expected to support long-term growth (See “Known
Trends and Uncertainties – New Processing Technology” for a discussion of our new PFAS-destruction technology).
We
are continually monitoring our operating costs to ensure alignment with our revenue levels.
Financial Results Overview
As a result of the combined factors discussed above, revenue decreased by $1,701,000, or 11.7%, to $12,885,000 for the three months ended June 30, 2026, from $14,586,000 for the same period of 2025. The decrease was primarily attributable to our Treatment Segment, where revenue declined by $3,108,000, or 27.3%, to $8,289,000 from $11,397,000 in the prior-year period. This decrease was partially offset by higher Services Segment revenue, which increased by $1,407,000, or 44.1%, to $4,596,000 from $3,189,000 in the same period of 2025. Cost of goods sold increased by $2,349,000, or 18.0%, to $15,388,000 for the three months ended June 30, 2026, compared to $13,039,000 for the same period of 2025. As a result, we incurred a gross loss of $2,503,000 for the three months ended June 30, 2026, compared with gross profit of $1,547,000 in the prior-year period. SG&A expenses decreased by $379,000 to $3,751,000 for the three months ended June 30, 2026, from $4,130,000 in the same period of 2025.
For the six months ended June 30, 2026, revenue decreased by $4,494,000, or 15.8%, to $24,011,000 from $28,505,000 for the same period of 2025. The decrease was primarily attributed to our Treatment Segment where revenue declined by $4,415,000. Services Segment revenue decreased slightly by $79,000 or 1.0% to $7,843,000 for the six months ended June 30, 2026 from $7,922,000 for the same period of 2025. Cost of goods sold increased by $3,094,000, or 11.8%, to $29,395,000 for the six months ended June 30, 2026, from $26,301,000 in the same period of 2025. As a result, we incurred a gross loss of $5,384,000 for the six months ended June 30, 2026, compared with gross profit of $2,204,000 in the prior-year period. SG&A expenses decreased by $96,000, or 1.2%, to $8,049,000 from $8,145,000 for the same period of 2025.
See below “Results of Operations” for a discussion of our financial results for the three and six months ended June 30, 2026 as compared to the corresponding period of 2025.
Despite the positive developments discussed above, management concluded that substantial doubt continues to exist about our ability to continue as a going concern within one year after the date the accompanying Condensed Consolidated Financial Statements are issued (see “Liquidity and Capital Resources” within this MD&A for a discussion of the factors and conditions underlying this conclusion).
Our
Treatment and Services Segments’ business continue to be heavily dependent on services that we provide to federal governmental
clients, primarily as subcontractors for others who are contractors to government entities or directly as the prime contractor. We believe
demand for our services will continue to be subject to fluctuations due to a variety of factors beyond our control, including, without
limitation, current economic and political conditions, government reductions, passage of government budgets, government shutdowns and
CRs, and the manner in which the applicable government authority will be required to spend funding to remediate various sites.control. In addition, our
our governmental contracts and subcontracts relating to activities at federal governmental sites are generally subject to termination for
for convenience at any time, at the government’s option. Significant reductions in the level of governmental funding, government shutdown
shutdown or specifically mandated levels for different programs that are important to our business could have a material adverse impact
on our
business, financial position, results of operations, liquidity and cash flows.
Summary
– Three and Six Months Ended MarchJune 31,30, 2026 and 2025
Consolidated
revenues decreased $2,793,000$1,701,000, for the three months ended MarchJune 31,30, 2026, compared to the three months ended MarchJune 31,30, 2025, as follows:
(1) Includes wastes generated by government clients of $702,000 and $567,000 for the three months ended June 30, 2026 and the corresponding period of 2025, respectively.
Treatment Segment revenue decreased by $3,108,000, or 27.3%, for the three months ended June 30, 2026, compared with the same period in 2025. The decline was primarily due to lower waste volume and a less favorable revenue mix. The less favorable revenue mix reflected lower average pricing, primarily resulting from the processing of certain previously stored waste inventories. These previously stored waste inventories were processed as part of our preparation for anticipated increases in Hanford-related waste volumes.
The increase in revenue in our Services Segment was primarily attributable to a higher volume of project work during the period compared with the same period in 2025. Revenue in our Services Segment is project-based and is influenced by the scope, duration, timing, and completion of individual projects. As a result, revenue may fluctuate significantly between reporting periods based on the timing, scope, and mix of projects performed.
Consolidated revenues decreased $4,494,000 for the six months ended June 30, 2026, compared to the six months ended June 30, 2025, as follows:
(1) Includes wastes generated by government clients of $1,214,000 and $1,007,000 for the six months ended June 30, 2026, and the corresponding period of 2025, respectively.
Treatment Segment revenue decreased by $4,415,000, or 21.4%, for the six months ended June 30, 2026, compared with the same period in 2025. The decline was primarily due to lower waste volumes and a less favorable revenue mix. The less favorable revenue mix reflected lower average pricing, which was impacted in part by the processing of certain previously stored waste inventories that carried lower average pricing. These previously stored waste inventories were processed as part of our preparation for anticipated increases in Hanford-related waste volumes.
The decrease in revenue in our Services Segment was primarily attributable to a lower volume of project work during the first quarter of 2026. The lower project volume reflected, in part, the impact of typical winter weather and post-holiday slowdowns that reduced field activity. Revenue in our Services Segment is project-based, and the scope, duration, timing, and completion of individual projects vary from period to period. As a result, revenue may fluctuate significantly between reporting periods based on the timing, scope, and mix of projects performed.
Treatment
Segment revenue decreased by $1,308,000 or 14.2%, for the three months ended March 31, 2026, compared to the same period in 2025. The
decline was due to lower waste volume from government- related customers, partially offset by increased waste volume from commercial
clients, reflecting efforts to expand our commercial customer base. Treatment Segment revenue was also negatively impacted from lower
averaged price waste mix. The decrease in revenue in the Services Segment was due to reasons as discussed in the “Overview”
section. Additionally, our Services Segment revenues are project-based, and therefore subject to variability in project scope, duration,
and timing of completion.
Cost
of goods sold increased $745,000$2,349,000 for the quarter ended MarchJune 31,30, 2026, compared towith the quartersame endedperiod March 31,in 2025, as follows:
Cost of goods sold for the Treatment Segment increased by approximately $1,110,000, or 11.3%. Variable costs increased by approximately $477,000, primarily due to higher materials and supplies, transportation, and outside services costs totaling approximately $444,000, as well as higher overtime expense of approximately $217,000 incurred in processing previously stored waste inventories in anticipation of increases in Hanford-related waste volumes. These increases were partially offset by lower disposal costs of approximately $184,000. Within our Treatment Segment, the composition and level of variable costs can fluctuate based on the waste mix. Treatment Segment fixed costs increased by approximately $633,000. Fixed salaries and payroll-related expenses increased by approximately $499,000, primarily due to COLA adjustments implemented in July 2025 and increased headcount. Maintenance costs increased by approximately $45,000 due to general equipment upkeep and facility security enhancements. Depreciation expense increased by approximately $59,000 due to additional capitalized equipment, including our prototype PFAS reactor. Regulatory expenses increased by approximately $74,000 due to increased regulatory activities and higher fees assessed by regulatory agencies. These increases were partially offset by a decrease of approximately $44,000 in general expenses, primarily due to lower utility costs.
Services Segment cost of goods sold increased by $1,239,000, or 38.6%, primarily due to higher revenue during the period. The increase was primarily driven by higher subcontract and outside services costs of approximately $655,000 and higher salaries and payroll-related expenses of approximately $419,000. The increase in salaries and payroll-related expenses primarily reflected the COLA implemented in July 2025, as well as increased labor associated with the higher volume of project work. Cost of goods sold also increased due to higher travel costs of approximately $118,000 and increased materials and supplies, disposal, and regulatory costs totaling approximately $108,000. These increases were partially offset by lower general expenses of approximately $48,000 across various categories and lower depreciation expense of approximately $13,000, as certain equipment became fully depreciated in 2025. Within our Services Segment, the composition and level of cost of goods sold are influenced by the type, scope, and timing of projects performed during the period. Certain projects require greater reliance on subcontractors, specialized materials, regulatory compliance activities, or travel, while others are more labor-intensive or utilize primarily in-house resources. As a result, the mix of project work can significantly affect both the composition and level of costs incurred and may not be directly proportional to changes in revenue.
Cost of goods sold increased $3,094,000, for the six months ended June 30, 2026, compared with the same period in 2025, as follows:
Cost of goods sold for the Treatment Segment increased by approximately $2,886,000, or 15.4%. Variable costs increased by approximately $1,686,000, primarily due to higher disposal, materials and supplies, transportation and lab costs totaling approximately $1,453,000, as well as higher overtime expense of approximately $233,000 incurred in processing previously stored waste inventories in anticipation of increases in Hanford-related waste volumes. Within our Treatment Segment, the composition and level of variable costs can fluctuate based on waste mix. Treatment Segment fixed costs increased by approximately $1,200,000. Fixed salaries and payroll-related expenses increased by approximately $810,000, primarily due to COLA adjustments implemented in July 2025 and increased headcount. Maintenance costs increased by approximately $127,000 due to general equipment upkeep and facility security enhancements. Depreciation expense increased by approximately $133,000 due to additional capitalized equipment, including our prototype PFAS reactor. Regulatory expenses increased by approximately $192,000 due to increased regulatory activities and higher fees assessed by regulatory agencies. These increases were partially offset by a decrease of approximately $62,000 in general expenses, primarily due to lower utility costs.
Services Segment cost of goods sold increased by $208,000, or 2.8%. The increase was primarily driven by higher salaries and payroll-related expenses of approximately $534,000, reflecting the COLA implemented in July 2025, as well as increased labor associated with the higher volume of project work. Cost of goods sold also increased due to higher travel costs of approximately $237,000. These increases were partially offset by lower outside services costs of approximately $276,000, lower materials and supplies, disposal and regulatory costs totaling approximately $171,000, lower general expenses of approximately $83,000 across various categories, and lower depreciation expense of approximately $33,000 as certain equipment became fully depreciated in 2025. Within our Services Segment, the composition and level of cost of goods sold are influenced by the type, scope, and timing of projects performed during the period. Certain projects require greater reliance on subcontractors, specialized materials, regulatory compliance activities, or travel, while others are more labor-intensive or utilize primarily in-house resources. As a result, the mix of project work can significantly affect both the composition and level of costs incurred and may not be directly proportional to changes in revenue.
Cost
of goods sold for the Treatment Segment increased by approximately $1,775,000, or 19.9%. Variable costs rose by approximately $1,209,000,
driven primarily by higher disposal costs of approximately $1,235,000, partially offset by lower transportation, materials and supplies,
and laboratory costs totaling approximately $26,000. Within our Treatment Segment, variable cost categories can fluctuate based on waste
mix. Treatment Segment’s overall fixed costs increased by approximately $566,000 resulting from the following: fixed salaries and
payroll related expenses were higher by $313,000 due to COLA implemented in July 2025; maintenance costs were higher by approximately
$81,000 due to general equipment upkeep and facility security enhancements; depreciation expenses were higher by $74,000 due to increased
capitalized equipment, including our prototype PFAS reactor; regulatory expenses were higher by approximately $117,000 due to increased
regulatory activities and higher fees from regulatory agencies; and overall general expenses were lower by $19,000 primarily due to lower
utility costs. Services Segment cost of goods sold decreased by $1,030,000, or 23.8%, primarily due to lower revenue. The decrease was
largely driven by reduced subcontract and outside services costs of approximately $931,000. Additional decreases included lower general
expenses of approximately $39,000 across various categories, reduced depreciation expense of approximately $20,000 as certain equipment
became fully depreciated in 2025, and an overall reduction in material and supplies, disposal, laboratory, and regulatory expenses totaling
approximately $275,000. These decreases were partially offset by higher salaries and payroll-related expenses of approximately $115,000
due to COLA implemented in July 2025, as well as increased travel expenses of approximately $120,000. Within our Services Segment, fluctuations
in expense categories are influenced by the type and scope of projects performed during the period. Certain projects require greater
reliance on subcontractors, specialized materials, regulatory compliance efforts, or travel, while others are more labor-driven or utilize
in-house resources. As a result, the mix of project work can significantly impact the composition and level of costs incurred. Included
within cost of goods sold is depreciation and amortization expense of $475,000 and $421,000 for the three months ended March 31, 2026,
and 2025, respectively.
Gross
profit decreased $3,538,000 for the quarter ended MarchJune 31,30, 2026,2026 compareddecreased to$4,050,000 over the quartersame endedperiod Marchin 31, 2025,2025 as follows:
Treatment Segment incurred a gross loss of $2,652,000 for the three months ended June 30, 2026, compared with a gross profit of $1,566,000 for the same period in 2025. Gross margin declined to (32.0%) from 13.7%. The decline in gross profit and gross margin was primarily due to lower revenue resulting from reduced waste volumes and a less favorable waste mix. In addition, the Treatment Segment’s higher fixed operating costs were spread over a lower revenue base, further reducing gross margin and contributing to the gross loss.
Services Segment gross profit increased by approximately $168,000, and gross margin improved to 3.2% from (0.6%) in the prior-year period, primarily due to higher revenue. Gross margins within our Services Segment are influenced by the type, scope, and mix of projects performed, which are generally competitively bid and have varying margin structures. As a result, gross margins may fluctuate from period to period based on the timing and mix of projects completed.
Gross profit for the six months ended June 30, 2026 decreased $7,588,000 over 2025 as follows:
Treatment Segment incurred a gross loss of $5,485,000 for the six months ended June 30, 2026, compared a gross profit of $1,816,000 for the same period of 2025. Gross margin declined to (33.9%) from 8.8%, primarily due to lower revenue from lower waste volume and a less favorable waste mix. In addition, higher operating fixed costs within the Treatment Segment, which were spread over a lower revenue base, further reduced gross margin and contributed to the gross loss.
Services Segment gross profit decreased by $287,000, and gross margin declined to 1.3% from 4.9% in the prior-year period, primarily due to lower revenue and a less favorable project margin mix. Gross margins within our Services Segment are influenced by the type, scope, and mix of projects performed, which are generally competitively bid and have varying margin structures. As a result, gross margins may fluctuate from period to period based on the timing and mix of projects completed.
Treatment
Segment gross profit decreased by $3,083,000 or approximately 1,233.2% and gross margin declined to (36.0%) from 2.7% primarily due to
lower revenue driven by lower waste volume and a less favorable waste mix. The increase in fixed costs within the Treatment Segment also
negatively impacted gross margin and contributed to the gross loss. Services Segment gross profit decreased by $455,000 or 111.8% and
gross margin decreased to (1.5%) from 8.6% mainly due to lower revenue, partially offset by reduced fixed costs. Additionally, overall
Services Segment gross margin is impacted by the nature of its projects, which are competitively bid and therefore have varying margin
structures.
SG&A
increasedexpenses $284,000decreased $379,000 for the three months ended MarchJune 31,30, 2026, as compared to the corresponding period for 2025, as follows:
Administrative SG&A increased primarily due to higher outside services costs associated with increased legal and business activities. Treatment Segment SG&A declined primarily due to lower salaries and payroll-related expenses as fewer employee hours were required to support administrative and marketing functions. Services Segment SG&A declined primarily due to a decrease in the provision for credit losses resulting from the settlement of a receivable that had previously been determined to be uncollectible, as well as lower salaries and payroll-related expenses due to fewer employee hours needed to support marketing functions.
SG&A expenses decreased $96,000 for the six months ended June 30, 2026, compared to the corresponding period for 2025, as follows:
Administrative SG&A increased primarily due to approximately $184,000 of higher outside services costs associated with increased legal and business activities. The remaining increase was primarily attributable to higher salaries and payroll-related expenses resulting from COLA implemented in July 2025 for employees and January 2026 for executives. Treatment Segment SG&A increased primarily due to approximately $53,000 of higher outside services costs associated with increased consulting and business activities and approximately $31,000 of higher travel expenses incurred by information technology personnel. These increases were partially offset by lower salaries and payroll-related expenses, as fewer employee hours were required to support administrative and marketing functions. Services Segment SG&A declined primarily due to a decrease in provision for credit losses resulting from the settlement of a receivable that had previously been determined to be uncollectible.
Administrative
SG&A increased primarily due to approximately $65,000 in higher salaries and payroll-related costs, driven by the addition of one
employee and COLA implemented in July 2025 for employees and January 2026 for executives. The remaining increase was attributable to
higher outside services costs associated with increased legal and business activities. Treatment Segment SG&A rose mainly due to
higher outside services costs of approximately $60,000 from increased consulting and business activities, as well as higher travel expenses
of about $23,000. In the Services Segment, SG&A increased primarily due to approximately $72,000 in higher salaries and payroll-related
costs, reflecting additional hours spent supporting bids and proposals. Outside services expenses also increased by about $20,000 due
to more consulting activities. These increases were partially offset by a reduction of approximately $11,000 in general expenses across
various categories. Included in SG&A is depreciation and amortization expense of $15,000 for the three months ended March 31, 2026,
and the corresponding period of 2025.
Interest
income decreased by approximately $155,000$98,000 and $252,000 for the three and six months ended June 30, 2026, respectively, compared with
the same periods in the2025. firstThe quarterdecreases of 2026 over to the corresponding period of 2025were primarily due lessto interest
income earned from reducing balances in the MMDA. Additionally, lesslower interest income wasearned on lower balances maintained in our MMDA.
Interest income also declined due to lower interest earned fromon theour finite risk sinking fundsfunds, fromprimarily as a result of lower interest
interest rates.
Interest
expense decreased by approximately $53,000$51,000 and $103,000 for the firstthree quarterand ofsix 2026months ended June 30, 2026, respectively, compared to with
the same periodperiods in 2025. The decreasedecreases waswere primarily
due to the capitalization of approximately $34,000$40,000 and $74,000 of interest in
the three and six months ended June 30, 2026, respectively, related to debt incurred for construction projects, including theour Company’ssecond
second PFAS reactor.
We
had no income tax expense for continuing operations of $0 for both the three and six months ended MarchJune 31,30, 2026,2026 and 2025. TheOur effective tax rate
was 0% infor botheach periods,period primarilyas duea toresult of the full valuation allowance recorded in 2024recognized against the Company’sits U.S. federal and state
deferred tax assets.assets
during the quarter ended September 30, 2024.
Backlog
Our
Treatment Segment maintains a backlog of stored waste, which represents waste that has not been processed. The backlog is principally
a result of the timing and complexity of the waste being brought into the facilities and the selling price per container. As of March
31, 2026, our Treatment Segment had a backlog of approximately $12,248,000, as compared to approximately $11,861,000 as of December 31,
2025. Treatment Segment backlog does not guarantee immediate revenue, as the timing of backlog processing may vary based on waste complexity,
customer requirements, and operational considerations.
Our cash flow requirements during the six months ended June 30, 2026, were funded primarily from available PNC Liquidity. Our PNC Liquidity includes cash held in our MMDA, which includes net proceeds from the sale of 2,628,571 shares of our Common Stock completed in May 2026 (see “Financing Activities” below within this MD&A and “Note 13—Sale of Common Stock” to the accompanying Condensed Consolidated Financial Statements for further discussion of the equity offering).
PESI insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
| Trade date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Wamp Zach Paul |
Grant/award | 775 | $11.74 | $9.1K |
| 2026-10-01 | Reeder Joe |
Grant/award | 1,289 | $11.74 | $15.1K |
| 2026-10-01 | Shelton Larry |
Grant/award | 1,246 | $11.74 | $14.6K |
| 2026-10-01 | Grumski Joseph Timothy |
Grant/award | 1,438 | $11.74 | $16.9K |
| 2026-10-01 | Bostick Thomas |
Grant/award | 1,108 | $11.74 | $13.0K |
| 2026-10-01 | Duggan Kerry C |
Grant/award | 748 | $11.74 | $8.8K |
| 2026-10-01 | Zwecker Mark A |
Grant/award | 1,038 | $11.74 | $12.2K |
| 2026-07-13 | Shelton Larry |
Option exercise | 2,400 | $4.60 | $11.0K |
| 2026-07-01 | Grumski Joseph Timothy |
Grant/award | 1,528 | $10.72 | $16.4K |
| 2026-07-01 | Zwecker Mark A |
Grant/award | 1,167 | $10.72 | $12.5K |
| 2026-07-01 | Bostick Thomas |
Grant/award | 1,213 | $10.72 | $13.0K |
| 2026-07-01 | Reeder Joe |
Grant/award | 1,458 | $10.72 | $15.6K |
| 2026-07-01 | Wamp Zach Paul |
Grant/award | 849 | $10.72 | $9.1K |
| 2026-07-01 | Shelton Larry |
Grant/award | 1,365 | $10.72 | $14.6K |
| 2026-07-01 | Duggan Kerry C |
Grant/award | 819 | $10.72 | $8.8K |
Well-known investors holding PESI (13F)
| Investor | Quarter | Shares | Reported value | % of their 13F | Change vs prior quarter |
|---|---|---|---|---|---|
| Citadel Advisors (Ken Griffin) | 2026-06-30 | 152,626 | $2.2M | 0.0% | Added 120% |
| D. E. Shaw & Co. | 2026-06-30 | 24,858 | $355.2K | 0.0% | Reduced 61% |